Evidence map›Paper›PMID 36516292›Full record

ArticleOrganic letters2022

Total Synthesis of Pargamicin A.

Yassin M Elbatrawi, Taylor Gerrein, Avraz Anwar, Kamlesh M Makwana, David Degen, Richard H Ebright, Juan R Del Valle

Abstract read
In one paragraph

Article in Organic letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Total Synthesis of Pargamicin A.Organic letters · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yassin M ElbatrawiDepartment of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.
Taylor GerreinDepartment of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.
Avraz AnwarDepartment of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.
Kamlesh M MakwanaDepartment of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.
David DegenWaksman Institute and Department of Chemistry & Chemical Biology, Rutgers University, Piscataway, New Jersey 08854, United States.
Richard H EbrightWaksman Institute and Department of Chemistry & Chemical Biology, Rutgers University, Piscataway, New Jersey 08854, United States.
Juan R Del ValleDepartment of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.ORCID 0000-0002-7964-8402

Funding

Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinolsU19AI142731 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI PERLIN, DAVID S · 2019 to 2023
$33.9M
Therapeutics for drug resistant-bacteria: Arylpropionyl-phloroglucinolsU19AI109713 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI PERLIN, DAVID S · 2014 to 2018
$26.9M
NIAID NIH HHS U19 AI109713NIAID NIH HHS U19 AI142731
6 · The paper itself

Abstract

We report the total synthesis and configurational assignment of pargamicin A, a highly oxidized nonribosomal peptide that potently inhibits the growth of drug-resistant bacteria. Our synthetic approach relies on late-stage piperazine ring formation and careful selection of condensation reagents to assemble the densely substituted hexapeptide backbone. This work enables the synthesis of pargamicin congeners for the development of structure-activity relationships and informs strategies for accessing other sterically congested piperazic acid-containing natural products.

Indexed as

Biological ProductsPeptides, CyclicPeptidesStructure-Activity RelationshipBiological Productspargamicin APeptidesPeptides, Cyclic

Identifiers

PMID36516292
PMCPMC10680435

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.